Get to know our clinical trials
Clinical trial of amivantamab and mFOLFOX6 or FOLFIRI vs. cetuximab and mFOLFOX6 or FOLFIRI as first-line treatment in patients with unresectable or metastatic left-sided colorectal cancer with KRAS/NRAS and wild-type BRAF.
THE AIM OF THIS STUDY IS TO COMPARE THE EFFECTS OF TWO ANTINEOPLASTIC DRUGS (AMIVANTAMAB AND CETUXIMAB) WHEN EACH IS ADMINISTERED IN COMBINATION WITH CONVENTIONAL COLORECTAL CANCER (CRC) CHEMOTHERAPIES TO PATIENTS WITH METASTATIC CRC WHO DO NOT HAVE MUTATIONS IN GENES CALLED KRAS/NRAS AND BRAF. TREATMENT WITH CETUXIMAB, FOLFIRI AND MFOLFOX6 IS ALREADY USED TO TREAT PATIENTS WITH HIS TYPE OF CANCER.
Technical Summary
- PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF AMIVANTAMAB AND MFOLFOX6 OR FOLFIRI VERSUS CETUXIMAB AND MFOLFOX6 OR FOLFIRI AS FIRST-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE OR METASTATIC LEFT-SIDED COLORECTAL CANCER WITH KRAS/NRAS AND WILD-TYPE BRAF. IMMUNOTHERAPY.
- Code EudraCT: 2024-513852-13
- Protocol number: 61186372COR3001
- Promoter: Janssen-Cilag
- Molecule/Drug: mFOLFOX6 o FOLFIRI
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.